The National Medical Products Administration (NMPA) has initiated enhancements to its conditional drug approval system, following a high-level meeting led by Li Li. The initiative aims to accelerate the availability of critical therapies, particularly for patients with unmet medical needs such as in oncology.
Key Highlights:
- Policy Focus:
- Strengthening and refining the conditional approval pathway to improve access to urgently needed drugs.
- Scope:
- Applicable to conditionally approved drugs, including innovative therapies and select generics.
- Key Reforms / Provisions:
- Revised Working Procedures: Approval of the “Working Procedures for the Review and Approval of Conditional Drug Marketing Applications (Revised Draft)” to standardize processes.
- Clearer Approval Standards: Enhanced clarity on eligibility and evaluation criteria for conditional approvals.
- Post-Marketing Commitments: Defined timelines and requirements for post-marketing studies to confirm safety and efficacy.
- Lifecycle Management: New provisions covering re-registration, generic drug applications, and marketing authorization holder changes.
- Focus on Critical Therapies: Continued prioritization of drugs addressing serious or life-threatening conditions, especially in oncology.
- Regulatory Goals:
- Accelerate patient access to life-saving treatments.
- Align with global regulatory practices and evolving innovation trends.
- Strengthen compliance, oversight, and patient protection mechanisms.
- Improve coordination with industry and address key implementation challenges.
Select Mandate HA
Select Mandate Function